Page 1

November 23 , 2021 IceCure IceCure Medical Reports Financial Results as of and for the first Nine Months of 2021 and Recent Corporate Developments CAESAREA , Israel , Nov. 23 , 2021 / PRNewswire / -- IceCure Medical Ltd. ( NASDAQ : ICCM ) ( TASE : ICCM ) ( " IceCure " or the " Company " ) , developer of next - generation , minimally- invasive cryoablation technology with ProSense® that destroys tumors by freezing as an alternative to surgical tumor removal , today reported its financial results as of and for the nine - month period ended September 30 , 2021 . Recent Corporate Developments • On September 13th , IceCure announced the first peer - reviewed article of its ICE3 Clinical Trial " Cryoablation Without Excision for Low - Risk , Early - Stage Breast Cancer : 3 - Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial " . The article was published in the Annals of Surgical Oncology by the lead author Dr. Richard Fine , M.D. , FACS , an ICE3 investigator who serves as Program Director of the Breast Surgical Oncology Fellowship and as Director of Research and Education at the West Comprehensive Breast Center in Germantown , Tennessee , as the lead author . • On October 12th , the Company submitted an amendment to the registration certificate for the IceSense3Ⓡ system to China's National Medical Products Administration ( " NMPA " ) , which , if approved , would allow the disposable IceSense3 Cryoprobes to be sold for commercial procedures in mainland China . Approval of the amendment is expected by the end of 2022 , which would be followed by a commercial sales program launch in China in early 2023 . • On October 20th , IceCure announced an expansion of the Company's global distribution network with an initial distribution agreement in Poland with Mobile SCANMED Systems SP . z o.o. ( " Mobile SCANMED Systems " ) to exclusively sell the ProSense® Cryoablation System and disposables . • On November 1st , the Company announced a peer - reviewed publication , " VAB and MRI Following Percutaneous Ultra - Sound Guided Cryoablation for Primary Early - Stage Breast Cancer : A Pilot Study in Japan " , that was published in the Journal of Cancer Therapy by lead author Dr. Hisanori Kawamoto , M.D. , Ph.D. from the Department of Breast Surgery Breast and Imaging Center , St. Marianna University School of Medicine , Japan . The published data from the independent study demonstrated that percutaneous cryoablation presents a potential substitute for lumpectomy of breast tumors < 15mm using ProSense . " This is an exciting time in IceCure's history , as we continue to generate increasing interest among a growing roster of leading commercial partners around the world to distribute our ProSense Cryoablation System , including forming recent distribution collaborations in